Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals Inc (NQ: CRNX )

19.92 -0.20 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 265,106
Open 19.95
Bid (Size) 7.980 (2)
Ask (Size) 28.95 (1)
Prev. Close 20.12
Today's Range 19.86 - 20.53
52wk Range 15.37 - 27.86
Shares Outstanding 53,810,476
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Crinetics Pharmaceuticals's Return On Capital Employed Overview
 
Via Benzinga

Performance

YTD
+10.06%
+10.06%
1 Month
+12.48%
+12.48%
3 Month
+14.68%
+14.68%
6 Month
-9.66%
-9.66%
1 Year
+10.85%
+10.85%

More News

Read More
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Crinetics' CRN04777 Shows Dose-Dependent Suppression of Fasting Insulin
Via Benzinga
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
From Crinetics Pharmaceuticals, Inc.
Via Globe NewsWire
Crinetics Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Crinetics Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
88 Biggest Movers From Yesterday
Via Benzinga
Crinetics Pharmaceuticals Announces Positive Top-line Results From CRN04894 Early-Stage Trial
Via Benzinga
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
53 Biggest Movers From Yesterday
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Last Week's Notable Insider Buys: Beacon Roofing Supply, Enfusion, Nerdy And More
Via Benzinga
52 Biggest Movers From Yesterday
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.